Hemostemix Other Stockholder Equity vs Total Stockholder Equity Analysis
HEM Stock | CAD 0.08 0.01 5.88% |
Hemostemix financial indicator trend analysis is much more than just examining Hemostemix latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Hemostemix is a good investment. Please check the relationship between Hemostemix Other Stockholder Equity and its Total Stockholder Equity accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemostemix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Other Stockholder Equity vs Total Stockholder Equity
Other Stockholder Equity vs Total Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Hemostemix Other Stockholder Equity account and Total Stockholder Equity. At this time, the significance of the direction appears to have pay attention.
The correlation between Hemostemix's Other Stockholder Equity and Total Stockholder Equity is -0.84. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Hemostemix, assuming nothing else is changed. The correlation between historical values of Hemostemix's Other Stockholder Equity and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of Hemostemix are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Other Stockholder Equity i.e., Hemostemix's Other Stockholder Equity and Total Stockholder Equity go up and down completely randomly.
Correlation Coefficient | -0.84 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Other Stockholder Equity
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most indicators from Hemostemix's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Hemostemix current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemostemix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Issuance Of Capital Stock is likely to climb to about 2.3 M in 2024, whereas Selling General Administrative is likely to drop slightly above 1.3 M in 2024.
Hemostemix fundamental ratios Correlations
Click cells to compare fundamentals
Hemostemix Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Hemostemix fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 104.3K | 2.3M | 563.0K | 465.3K | 313.8K | 298.1K | |
Other Current Liab | 2.1M | 3.2M | 1.0M | 2.6M | 3.0M | 3.2M | |
Total Current Liabilities | 4.1M | 3.4M | 4.4M | 2.6M | 2.9M | 2.4M | |
Total Stockholder Equity | (4.0M) | (1.1M) | (5.3M) | (6.8M) | (7.4M) | (7.0M) | |
Net Tangible Assets | 487.8K | (4.0M) | (1.1M) | (6.8M) | (6.1M) | (5.8M) | |
Net Debt | 2.0M | (83.0K) | 1.3M | 4.0M | 4.2M | 4.4M | |
Retained Earnings | (41.5M) | (49.2M) | (55.5M) | (60.8M) | (63.3M) | (60.1M) | |
Accounts Payable | 2.1M | 3.2M | 4.4M | 2.4K | 2.9M | 1.6M | |
Cash | 24.1K | 258.0K | 219.4K | 135.7K | 155.4K | 147.6K | |
Non Current Assets Total | 4.5K | 2.0K | 902.0 | 407.0 | 184.0 | 174.8 | |
Cash And Short Term Investments | 24.1K | 258.0K | 219.4K | 135.7K | 155.4K | 147.6K | |
Net Receivables | 75.8K | 2.1M | 342.7K | 138.9K | 25.1K | 23.8K | |
Common Stock Shares Outstanding | 15.0M | 32.2M | 57.4M | 70.0M | 82.5M | 86.6M | |
Liabilities And Stockholders Equity | 104.3K | 2.3M | 563.0K | 465.3K | 313.8K | 298.1K | |
Inventory | (88.2K) | (13.3K) | (45.5K) | (342.7) | (394.1) | (413.81) | |
Other Current Assets | 13.3K | 45.5K | 342.7 | 190.3K | 133.1K | 101.6K | |
Other Stockholder Equity | 6.0M | 8.7M | 10.1M | 10.2M | 11.9M | 12.5M | |
Total Liab | 4.1M | 3.4M | 5.8M | 7.2M | 7.7M | 8.1M | |
Total Current Assets | 99.8K | 2.3M | 562.1K | 464.9K | 313.6K | 297.9K | |
Accumulated Other Comprehensive Income | 439.7K | 1.5M | 1.5M | 2.7M | 1.5M | 1.5M | |
Net Invested Capital | (2.0M) | (923.7K) | (3.8M) | (2.6M) | (3.0M) | (2.9M) | |
Net Working Capital | (4.0M) | (1.1M) | (3.8M) | (2.2M) | (2.6M) | (2.4M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Hemostemix Stock Analysis
When running Hemostemix's price analysis, check to measure Hemostemix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemostemix is operating at the current time. Most of Hemostemix's value examination focuses on studying past and present price action to predict the probability of Hemostemix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemostemix's price. Additionally, you may evaluate how the addition of Hemostemix to your portfolios can decrease your overall portfolio volatility.